Antibodies play a key role in the immune system and our response to vaccines, and have shown great promise as biotherapeutics. The development of new biotherapeutics typically takes many years and requires over $1bn in investment. Computational methods and in particular, machine learning, have shown great promise for increasing the speed and reducing the cost of biotherapeutic development.

In this talk I will describe some of the novel computational tools and databases we are pioneering in biotherapeutics from accurate rapid structure prediction to the prediction of their affinity and binding, looking at both their promise and limitations.